ERC Consolidator Grant · 2022
Mechanism and targeting of topoisomerase regulatory interactions to arrest MYC-driven tumors
Inhibitors of DNA topoisomerases (TOPs, TOP1, TOP2) are mainstays of anticancer therapy. While they have proven effective, the toxicity of current TOP drugs, caused by DNA damage-induced apoptosis of non-cancer cells, limits their use in clinic. Development of tumour-specific TOP inhibitors will require a better knowledge of the mechanisms of TOPs. This research program aims to define how TOP are regulated during transcription and replication and develop drugs that target these regulatory mechanisms for anticancer treatment. TOPs promote transcription and replication by removing DNA supercoiling generated during polymerase elongation. In my works published in Cell and Molecular Cell, I have…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.